Cardiovascular Systems permanently appoints interim leader as CEO

After searching for more than eight months for a new CEO, Cardiovascular Systems ended up choosing an employee of its own to permanently take over the position effective immediately.

Scott Ward, 56, who has been serving as the company’s chairman for nearly two years, has been the interim president and CEO since November 2015. Because of his knowledge of the company and proven track record that he could get the job done, Cardiovascular Systems appointed him permanently in the roles, the company said in a statement.

“As a director, Scott brings invaluable leadership and industry expertise to this organization,” said Leslie Trigg, chair of CSI’s Governance/Nominating Committee, in a statement. “His knowledge of the company runs deep as does his commitment to its success. We look forward to supporting Scott in this new role.”

Cardiovascular Systems, based in St. Paul, Minnesota, develops and commercializes medical devices that treat vascular and coronary disease.

“I am pleased with the progress Cardiovascular Systems has made to improve the quality of care for patients with coronary and peripheral artery disease,” said Ward, who joined the company’s board in 2013. “I look forward to continuing to serve our patients, customers and shareholders by helping [Cardiovascular Systems] achieve profitability and reach its full potential.”

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.